NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage company focused on promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025.
"Our encouraging data readouts for CRB-701 and CRB-913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026. This summer we anticipate key data readouts for both programs that we expect will elucidate their differentiated efficacy and safety profiles, as well as potential clinical utility and commercial opportunities," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "The clinical responses we are generating in HNSCC and cervical cancer patients with CRB-701, a highly stable Nectin-4 ADC, highlight its potential in treating these challenging tumor types. In parallel, the rapid weight loss and favorable GI tolerability we've seen with CRB-913 suggest it could provide a novel long-term weight management solution for people struggling with chronic obesity."
Key Corporate and Program Updates
CRB-701 is a next-generation, highly stable Nectin-4 targeting ADC being developed to treat HNSCC and cervical cancer. The U.S. Food and Drug Administration (FDA) has granted Fast Track designations to CRB-701 for the treatment of both cancer types. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.
CRB-913 is a highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity.
CRB-601 is an anti-αvβ8 integrin monoclonal antibody (mAB) designed to block the activation of latent TGFβ in the tumor micro-environment to treat solid tumors.
Financial Results for the Quarter and Year Ended December 31, 2025
The Company reported a net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, for the three months ended December 31, 2025, compared to a net loss of $9.5 million, or a net loss per basic and diluted share of $0.78, for the three months ended December 31, 2024.
Operating expenses increased by $9.4 million to approximately $22.0 million for the three months ended December 31, 2025, compared to approximately $12.6 million for the three months ended December 31, 2024. The increase was primarily attributable to an increase in clinical development expenses.
The Company had $163.3 million of cash, cash equivalents, and investment on hand at December 31, 2025, which is expected to fund operations into 2028 based on planned expenditures. In the fourth quarter of 2025, the Company completed a public offering that raised a total of $75 million in gross proceeds.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com
---tables to follow---
| Corbus Pharmaceuticals Holdings, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) | ||||||||||||||||
| Unaudited For the Three Months Ended December 31, | For the Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 18,406 | $ | 8,787 | $ | 70,095 | $ | 32,222 | ||||||||
| General and administrative | 3,560 | 3,818 | 15,215 | 16,499 | ||||||||||||
| Total operating expenses | 21,966 | 12,605 | 85,310 | 48,721 | ||||||||||||
| Operating loss | (21,966 | ) | (12,605 | ) | (85,310 | ) | (48,721 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest and investment income, net | 1,410 | 1,782 | 5,530 | 6,311 | ||||||||||||
| Interest expense | — | — | — | (1,872 | ) | |||||||||||
| Other income, net | 1 | 1,293 | 1,243 | 4,073 | ||||||||||||
| Total other income, net | 1,411 | 3,075 | 6,773 | 8,512 | ||||||||||||
| Net loss | $ | (20,555 | ) | $ | (9,530 | ) | $ | (78,537 | ) | $ | (40,209 | ) | ||||
| Net loss per share, basic and diluted | $ | (1.25 | ) | $ | (0.78 | ) | $ | (5.90 | ) | $ | (3.68 | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | 16,482,734 | 12,179,482 | 13,317,116 | 10,915,413 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (20,555 | ) | $ | (9,530 | ) | $ | (78,537 | ) | $ | (40,209 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Change in unrealized (loss) gain on marketable debt securities | (50 | ) | (172 | ) | (88 | ) | 36 | |||||||||
| Total other comprehensive (loss) income | (50 | ) | (172 | ) | (88 | ) | 36 | |||||||||
| Total comprehensive loss | $ | (20,605 | ) | $ | (9,702 | ) | $ | (78,625 | ) | $ | (40,173 | ) | ||||
| Corbus Pharmaceuticals Holdings, Inc. Consolidated Balance Sheets (in thousands, except share and per share amounts) | ||||||||
| December 31, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,492 | $ | 17,198 | ||||
| Investments | 134,777 | 131,864 | ||||||
| Restricted cash | 670 | 285 | ||||||
| Prepaid expenses and other current assets | 3,015 | 3,629 | ||||||
| Total current assets | 166,954 | 152,976 | ||||||
| Restricted cash | — | 385 | ||||||
| Property and equipment, net | 159 | 385 | ||||||
| Operating lease right-of-use assets | 1,082 | 2,133 | ||||||
| Total assets | $ | 168,195 | $ | 155,879 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,215 | $ | 4,786 | ||||
| Accrued expenses | 16,844 | 5,426 | ||||||
| Operating lease liabilities, current | 1,633 | 1,606 | ||||||
| Total current liabilities | 20,692 | 11,818 | ||||||
| Operating lease liabilities, noncurrent | — | 1,633 | ||||||
| Total liabilities | 20,692 | 13,451 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — | ||||||
| Common stock, $0.0001 par value; 300,000,000 shares authorized, 17,611,511 and 12,179,482 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 2 | 1 | ||||||
| Additional paid-in capital | 702,984 | 619,285 | ||||||
| Accumulated deficit | (555,430 | ) | (476,893 | ) | ||||
| Accumulated other comprehensive (loss) gain | (53 | ) | 35 | |||||
| Total stockholders' equity | 147,503 | 142,428 | ||||||
| Total liabilities and stockholders' equity | $ | 168,195 | $ | 155,879 | ||||
